Repapeace 1V 0.3 combines Repaglinide (1 mg) and Voglibose (0.3 mg) to effectively manage blood sugar levels in individuals with type 2 diabetes. Repaglinide stimulates insulin secretion from the pancreas while Voglibose slows carbohydrate absorption in the intestines. This dual-action formulation helps improve glycemic control making it an ideal choice for patients seeking comprehensive management of their diabetes.
Reviews
There are no reviews yet.